PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY

Published:2019-09 Issue:9 Volume:39 Page:1646-1654
ISSN:0275-004X
Container-title:Retina
language:en
Short-container-title:

Author:

Bressler Susan B.,Beaulieu Wesley T.,Glassman Adam R.,Gross Jeffrey G.,Melia Michele,Chen Eric,Pavlica Michael R.,Jampol Lee M.,

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Ophthalmology,General Medicine

Reference15 articles.

1. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years;Klein;Arch Ophthalmol,1984

2. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis;Stratton;Diabetologia,2001

3. Treatment of diabetic retinopathy;Ferris;N Engl J Med,1999

4. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial;Gross;JAMA,2015

5. Factors associated with worsening proliferative diabetic retinopathy in eyes treated with panretinal photocoagulation or ranibizumab;Bressler;Ophthalmology,2017

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Introduction of Diabetic retinopathy and principles of treatment;Therapeutic Targets for Diabetic Retinopathy;2024

2. Update on the Management of Diabetic Retinopathy: Anti-VEGF Agents for the Prevention of Complications and Progression of Nonproliferative and Proliferative Retinopathy;Life;2023-04-27

3. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy;Cochrane Database of Systematic Reviews;2023-03-20

4. Outcomes of 35-year duration of type 1 diabetes and proliferative diabetic retinopathy on functional vision and quality of life: Benefits of good glycemic control;Journal of Diabetes and its Complications;2023-02

5. Advances in Early Diabetic Retinopathy and before and after PRP on Visual Function Detection;Advances in Clinical Medicine;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3